Lv41
620 积分 2025-01-07 加入
Clinical toxicity of ADCs and ICI–ADC combinations: mechanisms, patterns and management
15天前
已完结
Antibody-Drug Conjugates Against Multidrug-Resistant Cancers: Biomarker-Guided Patient Selection, Payload Engineering, Linker Chemistry, and Bystander Effects
20天前
已完结
CAR T cells produced in vivo to treat cardiac injury
1个月前
已完结
Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial
1个月前
已完结
Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial
1个月前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
1个月前
已完结
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
2个月前
已完结
The role of hydrophilic linkers in next-generation antibody-drug conjugates
2个月前
已完结
Antibody–Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond
2个月前
已完结
The future promise of antibody–drug conjugates in extensive-stage small cell lung cancer
2个月前
已完结
皖公网安备34019202002308
